Descripción del proyecto
Nuevos biomarcadores del metabolismo energético en la depresión
Existen indicios recientes de que el trastorno depresivo mayor (TDM) está relacionado con una menor producción de energía y la alteración de la homeostasis del oxígeno en la mitocondria, así como con niveles elevados de actividad inflamatoria y estrés oxidativo. El objetivo principal del proyecto MitO2Health, financiado con fondos europeos, es investigar los mecanismos fisiológicos que subyacen al TDM. Los investigadores compararán el estado clínico y biológico de pacientes sometidos a terapia cognitivo-conductual con el de otras personas no tratadas y controles sanos. El estudio ayudará a identificar biomarcadores relacionados con la respuesta a la terapia individual y la recaída y, por ende, contribuirá al desarrollo de nuevos criterios diagnósticos con base biológica para el TDM. Además, allanará el camino para el desarrollo de conceptos de tratamiento innovadores.
Objetivo
MitO2Health aims to develop and empirically prove a radically new pathophysiological model of Major Depressive Disorder (MDD) as a systemic energy deficiency disease. Traditionally, MDD is conceptualized as a neurotransmitter deficiency in the brain. However, with pioneering methods my group has provided evi-dence for reduced mitochondrial energy production in MDD, characterizing it as a cellular-metabolic disorder with a lowered production of adenosine triphosphate (ATP). Reduced mitochondrial bioenergy production and impairments in oxygen (O2) homeostasis (reduced levels of erythrocytes, less hemoglobin and its lower O2-binding affinity due to oxidative stress), as well as oxidative stress and inflammation (the “MitO2Health parameters”) were consistently associated with an increased risk for MDD, but have been neglected so far in MDD research and therapy. In MitO2Health we will more comprehensively than ever before investigate the physiological mechanisms underlying MDD and will provide first longitudinal evidence on the mutual in-terplay between the MitO2Health parameters and MDD. Moreover, we will apply cognitive-behavioral therapy (CBT) as randomized treatment condition to test whether CBT-related MDD symptom reduction is coupled to a normalization of the MitO2Health parameters. We will treat 100 MDD patients with 6 months of CBT and compare them to 100 MDD patients of a waiting-list group and 100 healthy controls. Clinical and biological status will be assessed at four points over 18 months. We will thus characterize the biomarker pro-files of MDD treatment response and resistance as well as MDD symptom recurrence during a follow-up pe-riod. MitO2Health will not only establish a modern etiological model of MDD, but also identify biomarkers of individual therapy response and relapse. This will lead to new diagnostic standards and inspire personalized MDD treatment concepts that will fundamentally improve clinical outcomes in psychotherapy and psychiatry.
Ámbito científico
Programa(s)
Régimen de financiación
ERC-COG - Consolidator GrantInstitución de acogida
89081 Ulm
Alemania